XSHG
600668
Market cap424mUSD
Jul 10, Last price
7.17CNY
1D
2.72%
1Q
-33.92%
Jan 2017
-57.17%
Name
Zhe Jiang Jian Feng Group Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1958 and based in Jinhua, China, Zhejiang Jianfeng Group Co., Ltd. is a diverse enterprise primarily engaged in the Chinese cement industry, providing both ordinary Portland and Portland slag cement. Beyond construction materials, Jianfeng Group manufactures a range of pharmaceutical goods. These encompass aspartic acid amlodipine tablets for managing hypertension; heart pills designed to alleviate symptoms of high blood pressure, dizziness, headaches, neck pain, coronary heart disease, angina, nervous headaches, and early sudden deafness; paroxetine hydrochloride tablets targeting anxiety associated with depression; vinegar acid chloride Finn zyban products to treat symptoms linked to osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; spray vials for individuals suffering from severe herpes zoster; and sodium hyaluronate eye drops for dry eye conditions. Its diverse portfolio further includes a variety of cable products. Among these are common insulated electric wires for general and household use (BV line), HYA series communication cables featuring copper cores and solid polyolefin insulation, network lines, RVV series main power cables, SYWV-75 series physical foaming cables, and other telecommunication wiring. The group also supplies health and wellness items, ranging from Boiling Jade Kim tea bags, Bomb sugar, Sangge tea, lyophilized Tianma pieces, and broken fungus spore powder, to various capsules like grape seed extract soft, Tianfu, vitamin E nutritional, Bone Thai, and Goodnight capsules. Completing its array of services, the company also manages warehousing and logistics. All its offerings reach customers via an established network of marketing and sales channels.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||